Mesenchymal stem cells derived from adipose tissue are not affected by renal disease

Kidney International

Volumn 82, Issue 7, 2012, Pages 748-758

  Rhijn, Marieke Roemeling Van ^a   Reinders, Marlies E J ^b   De Klein, Annelies ^a   Douben, Hannie ^a   Korevaar, Sander S ^a   Mensah, Fane K F ^a   Dor, Frank J M F ^a   Ijzermans, Jan N M ^a   Betjes, Michiel G H ^a   Baan, Carla C ^a   Weimar, Willem ^a   Hoogduijn, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

end stage renal disease; immunosuppression; kidney transplantation; stem cell; uremia

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD31 ANTIGEN; CD45 ANTIGEN; CD72 ANTIGEN; ENDOGLIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA;

ADIPOSE DERIVED STEM CELL; ADULT; AGED; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; KARYOTYPING; KIDNEY DISEASE; MALE; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUBCUTANEOUS FAT; UREMIA;

EID: 84866380251     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.187     Document Type: Article

References (46)

1. Toma JG, Akhavan M, Fernandes KJ et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001; 3: 778-784.
2. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295.
3. Hoogduijn MJ, Crop MJ, Peeters AM et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597-604.
4. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
5. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
6. Maumus M, Peyrafitte JA, D'Angelo R et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes 2011; 35: 1141-1153.
7. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
8. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
9. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
11. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
12. Hoogduijn MJ, Popp F, Verbeek R et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 2010; 10: 1496-1500.
13. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 2004; 103: 4619-4621.
14. Togel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183.
15. Reinders ME, Fibbe WE, Rabelink TJ. Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation. Nephrol Dial Transplant 2010; 25: 17-24.
16. De Martino M, Zonta S, Rampino T et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation. Transplant Proc 2010; 42: 1331-1335.
17. Crop M, Baan C, Weimar W et al. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 2009; 22: 365-376.
18. Perico N, Casiraghi F, Introna M et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412-422.
19. Zhang W, Qin C, Zhou ZM. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. Transplant Proc 2007; 39: 3404-3408.
20. Hauser AB, Stinghen AE, Kato S et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008; 28(Suppl 3): S183-S187.
21. Berglund D, Korsgren O, Lorant T et al. Isolation, expansion and functional assessment of CD4+CD25+FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation. Transpl Immunol 2012; 26: 27-33.
22. Bacigalupo A, Valle M, Podesta M et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33: 819-827.
23. Jorgensen C, Djouad F, Fritz V et al. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine 2003; 70: 483-485.
24. Bocelli-Tyndall C, Bracci L, Spagnoli G et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-and allogeneicstimulated lymphocytes in vitro. Rheumatology 2007; 46: 403-408.
25. Perez-Simon JA, Tabera S, Sarasquete ME et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009; 11: 698-705.
26. Mallam E, Kemp K, Wilkins A et al. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010; 16: 909-918.
27. Bernardo ME, Avanzini MA, Ciccocioppo R et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 2009; 11: 825-836.
28. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-1669.
29. de Groot K, Bahlmann FH, Sowa J et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641-646.
30. de Groot K, Bahlmann FH, Bahlmann E et al. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 2005; 79: 941-945.
31. Grimes BR, Steiner CM, Merfeld-Clauss S et al. Interphase FISH demonstrates that human adipose stromal cells maintain a high level of genomic stability in long-term culture. Stem Cells Dev 2009; 18: 717-724.
32. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006; 11: 36-41.
33. Crop MJ, Baan CC, Korevaar SS et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162: 474-486.
34. Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrowderived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69: 5331-5339.
35. Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-3039.
36. Torsvik A, Rosland GV, Svendsen A et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects crosscontamination: putting the research field on track-letter. Cancer Res 2010; 70: 6393-6396.
37. Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 9142-9149.
38. Crop MJ, Korevaar SS, de Kuiper R et al. Human mesenchymal stem cells are susceptible to lysis by CD8+ T-cells and NK cells. Cell Transplant 2011; 20: 1547-1559.
39. Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120.
40. Crop MJ, Baan CC, Korevaar SS et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87: 896-906.
41. Hendrikx TK, van Gurp EA, Mol WM et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009; 24: 1969-1978.
42. Hoogduijn MJ, Crop MJ, Peeters AM et al. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant 2009; 9: 222-230.
43. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: an International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. International Standing Committee on Human Cytogenetic Nomenclature: Basel, Karger, 2009.
44. van Dekken H, Pizzolo JG, Reuter VE et al. Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes. Cytogenet Cell Genet 1990; 54: 103-107.
45. Veenma DC, Eussen HJ, Govaerts LC et al. Phenotype-genotype correlation in a familial IGF1R microdeletion case. J Med Genet 2010; 47: 492-498.
46. Peiffer DA, Le JM, Steemers FJ et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 2006; 16: 1136-1148.